Generic Name: Levetiracetam

Regulatory Class: Rx

Formulations: 250mg; 500mg; 1g Film Coated Tablet

Indications or Uses: Partial onset seizures w/ or w/o secondary generalisation in adults & adolescents 16 yr w/ newly diagnosed epilepsy. Adjunctive therapy in the treatment of partial onset seizures w/ or w/o secondary generalisation in adults, adolescents, childn & infants from 1 mth w/ epilepsy; myoclonic seizures in adults & juvenile myoclonic seizures in adolescents from 12 yrs; primary generalised tonic-clonic seizures in adults & idiopathic generalised epilepsy in adolescents from 12 yr.

Dosage or Directions for use:  Monotherapy for adult & adolescent from 16 yr Initially 250 mg bid, increased to 500 mg bid after 2 weeks, dose can be further increased by 250 mg bid every 2 weeks depending on the clinical response. Max: 1,500 mg bid. Add-on therapy for adult (≥18 yrs) & adolescent (12-17 yrs) weighing ≥50 kg Initially 500 mg bid in the 1st day of treatment. Dose may be increased to 1,500 mg bid. Dose may be increase or decrease to 500 mg bid every 2-4 wk. Childn & adolescent ≥50 kg Adult dose, 25 kg 250 mg bid. Max: 750 mg bid.

Administration: take w/ or w/o food. 

Contraindications: Hypersensitivity to levetiracetam or other pyrrolidone derivatives.

Special Precautions: Neutropenia, agranulocytosis, leukopenia, thrombocytopenia & pancytopenia. Increased risk of suicidal thoughts & behaviour; monitor for signs of depression &/or suicidal ideation & behaviour. Renal impairment. Acute kidney injury. Minor or moderate influence on the ability to drive & machines. Pregnancy & lactation. Not adapted for use in infants & childn <6 yr.

Adverse Reaction:  Nasopharyngitis, somnolence, headache, fatigue & dizziness. Anorexia; depression, hostility/aggression, anxiety, insomnia, nervousness/irritability; convulsion, balance disorder, lethargy, tremor; vertigo; cough; abdominal pain, diarrhoea, dyspepsia, vomiting, nausea; rash.

Interactions: Decrease methotrexate clearance resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Decreased efficacy w/ macrogol.

Presentation or Packaging: Film Coated Tablet 250 mg x 60's ; 500 mg x 60's; 1 g x 60's

For more information on this product, please see the product insert.